NAD+ and Sermorelin from Compounding Pharmacies: Legitimate Add-Ons or Upsells?

If you've browsed GLP-1 telehealth platforms recently, you've noticed that many now offer more than just semaglutide. NAD+ injections, sermorelin, and various "longevity peptides" are marketed alongside GLP-1 prescriptions — sometimes bundled as premium packages, sometimes offered as add-ons. The pitch is appealing: enhance your GLP-1 results with complementary therapies that support energy, recovery, and anti-aging.

But are these add-ons clinically justified, or are they revenue-maximizing upsells from platforms that need higher average order values to sustain their business models? The answer depends on the specific compound, the evidence behind it, and the patient's individual situation.

NAD+ (Nicotinamide Adenine Dinucleotide)

NAD+ is a coenzyme found in every cell of your body, critical for energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline with age, and this decline has been linked to various age-related metabolic changes. Supplementing NAD+ — through intravenous infusions, subcutaneous injections, or oral precursors — has become a cornerstone of the "longevity medicine" movement.

What the Evidence Shows

NAD+ research is in its early stages for most clinical applications. Animal studies have shown promising results: restored NAD+ levels improved metabolic function, enhanced mitochondrial activity, and extended lifespan in mouse models. Human data is more limited:

• Small human trials using NAD+ precursors (NR, NMN) have demonstrated that oral supplementation can increase blood NAD+ levels. Whether this translates to clinical benefits is still under investigation.
• Injectable NAD+ bypasses the digestive system, achieving higher blood levels more rapidly than oral supplementation. However, no large-scale randomized controlled trials have established clinical efficacy for injectable NAD+ in humans for any specific indication.
• The FDA has not approved NAD+ for any therapeutic indication. It is available through compounding pharmacies as a compounded preparation, not as an approved drug.

As a GLP-1 Companion

The marketing pitch is that NAD+ supports the metabolic demands of rapid weight loss — replenishing cellular energy pathways as the body adapts to reduced caloric intake and shifts in fat metabolism. This rationale has biochemical plausibility but no clinical trial evidence specific to GLP-1 patients. No study has compared GLP-1-plus-NAD+ outcomes to GLP-1 alone.

Sermorelin

Sermorelin is a growth hormone-releasing hormone (GHRH) analog — a peptide that stimulates the pituitary gland to produce more growth hormone (GH). It was FDA-approved in 1997 as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the branded product was discontinued in 2008 for commercial reasons. It remains available through compounding pharmacies.

What the Evidence Shows

Sermorelin has a stronger evidence base than NAD+ for its primary mechanism: it reliably stimulates growth hormone release in patients with intact pituitary function. The clinical question is whether the downstream effects of modestly increased GH — potentially including improved body composition, sleep quality, and recovery — are meaningful for adults using GLP-1 medications.

• Growth hormone supports lean mass preservation and fat metabolism. During rapid weight loss on GLP-1s, patients lose both fat and lean mass. The theoretical case for sermorelin is that boosting GH could shift the ratio toward more fat loss and less muscle loss.
• No clinical trial has tested sermorelin specifically as an adjunct to GLP-1 therapy for lean mass preservation. The hypothesis is mechanistically sound but clinically unvalidated.
• Sermorelin's safety profile is well-established from its years as an FDA-approved product. Common side effects include injection site reactions and headache.

Regulatory Considerations

Sermorelin's regulatory status is complicated by the FDA's evolving position on compounded peptides. While sermorelin itself is not a controlled substance, the FDA has expressed concern about the broader compounded peptide market and has taken enforcement actions against some compounders of growth hormone-related peptides. Patients using compounded sermorelin should ensure it comes from a licensed pharmacy with proper prescriber oversight.

The Business Model Behind Add-Ons

GLP-1 telehealth platforms face margin pressure. Compounded semaglutide has become commoditized — dozens of platforms offer essentially the same product at competitive prices. Add-on peptides and supplements create differentiation and higher average order values. A platform charging $199/month for semaglutide alone might charge $399/month for a "premium metabolic optimization package" that includes NAD+ and sermorelin — tripling the order value while the additional compounding cost is modest.

This business reality doesn't make the add-ons inherently bad — it means patients should evaluate them on clinical merit rather than marketing appeal. A prescriber who recommends sermorelin after reviewing your lab work, body composition data, and treatment goals is practicing medicine. A checkout screen that offers "Add NAD+ for $99/month" with no prescriber review is selling a product.

Providers Offering Peptide Add-On Consultations